A Frontline Clinician's Guide to Managing Opioid-Induced Constipation

Slides:



Advertisements
Similar presentations
Multimodal Management of Opioid-Induced Constipation
Advertisements

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Moderate-to-Severe Asthma Management
Immunotherapies: Key Considerations in the Identification and Management of irAEs.
Clinical Trials in IBD.
New Psoriasis Treatments
Why Gene Therapy for Hemophilia?
Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.
Unraveling Clinical Developments in NASH
Advances in Managing Inhibitors in Patients With Hemophilia A
Exploring the Spectrum of Excessive Daytime Sleepiness
Progression After Cancer Immunotherapy in Advanced NSCLC
Disclaimer. LEGAL AND POLICY CONSIDERATIONS OF NALOXONE FOR OPIOID TOXICITY REVERSAL.
Understanding the Many Faces of Pseudobulbar Affect
Clues to a Diagnosis: A Focus on Light-Chain Amyloidosis
Ask the Onychomycosis Expert, Part 2
Why Treat Seborrheic Keratosis?
Improving Acne Outcomes
Updates in Management of Atopic Dermatitis From Real Patient Cases
Advances in Dry Eye.
Before and After: Patient Cases in Onychomycosis
Induction Chemotherapy for Patients With High-Risk or Secondary AML
Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.
Treating Transplant-Ineligible Patients With Multiple Myeloma
Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.
Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.
The Resurgence of Topical Treatments Across a Spectrum of Psoriasis
Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.
Chronic Idiopathic Urticaria
Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma
The Nurse View.
Addressing Disease Burden in Asthma
Optimizing Management of Advanced Bladder Cancer
Seizures in the Elderly: Treatment and Special Considerations
Improving Outcomes in OSA
The Emerging Role of Immunotherapy in Hodgkin Lymphoma
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Next-Gen Psoriasis Therapies:
Hyperhidrosis Is Burdensome!
Gene Therapy: Past, Present, and Future
Tackling Atopic Dermatitis
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Immunotherapy for cSCC
Perspectives on the Impact of Inflammation in OA
Optimizing Frontline Care for Older Patients With Multiple Myeloma
Battling Constipation
Updates in Neurogenic Orthostatic Hypotension
Best Practices in the Clinical Management of Motor Symptoms Associated With Huntington Disease.
New Recommendations on How to Stage Hidradenitis Suppurativa
When Is Biologic Therapy Appropriate for HS?
Parkinson Disease Psychosis
Advances in Immunotherapy for Peanut Allergy
Guide to Atopic Dermatitis
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
EGPA.
The Burden of Psoriasis:
Optimizing Joint Health in Hemophilia
The Psychiatrist's Role in Tardive Dyskinesia
Pregnancy in MS.
Patient and Clinician Perspectives on Preventive Therapy for Migraine
Novel Concepts in the Management of RCC
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
The Psychiatrist's Role in Tardive Dyskinesia
Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition
Checkpoint Inhibitors in First-Line Advanced NSCLC
VKA Reversal and LVADs.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
What's New in PAH?.
Immune Checkpoint Inhibitors in Lung Cancer
Motor Fluctuations in PD
Presentation transcript:

A Frontline Clinician's Guide to Managing Opioid-Induced Constipation

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US.

Introduction

Annual Opioid Prescribing Rates: 2006-2016

Opioids Are Associated With Many Common AEs

Opioid-Induced Constipation

What Is OIC?

Pathogenesis of OIC

Working Definitions for OIC

Assessment and Diagnosis: Tools for Stools

Opioid-Related Constipation

Overlapping Nature of Constipation

Standard Treatment Protocols: Constipation

Differentiating OIC From OEC

Case 1: 78-Year-Old Maria

Case 2: 45-Year-Old Jennifer

Bristol Stool Chart

BFI

Who Is Responsible for Managing OIC?

Patient-Provider(s) Partnership for OIC Management

Management Strategies

Case 1 Reminder: Maria (Aged 78 Years)

Case 1: Management for Maria (Aged 78 Years)

Commonly Used Laxatives to Treat Constipation

Currently Approved Therapies

Currently Approved Therapies (cont)

Case 2 Reminder: Jennifer (Aged 45 Years)

Case 2: Management for Jennifer (Aged 45 Years)

Proposed Treatment Algorithm: OEC Based on Responsiveness to Initial Therapy

Proposed Real-World Treatment Algorithm: Opioid Constipation-Naive to Therapy

Key Messages

Abbreviations

Abbreviations (cont)